These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 27564544)

  • 1. A chimeric virus created by DNA shuffling of the capsid genes of different subtypes of porcine circovirus type 2 (PCV2) in the backbone of the non-pathogenic PCV1 induces protective immunity against the predominant PCV2b and the emerging PCV2d in pigs.
    Matzinger SR; Opriessnig T; Xiao CT; Catanzaro N; Beach NM; Slade DE; Nitzel GP; Meng XJ
    Virology; 2016 Nov; 498():82-93. PubMed ID: 27564544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel chimeric porcine circovirus (PCV) with the capsid gene of the emerging PCV2b subtype cloned in the genomic backbone of the non-pathogenic PCV1 is attenuated in vivo and induces protective and cross-protective immunity against PCV2b and PCV2a subtypes in pigs.
    Beach NM; Ramamoorthy S; Opriessnig T; Wu SQ; Meng XJ
    Vaccine; 2010 Dec; 29(2):221-32. PubMed ID: 21044670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A candidate DNA vaccine encoding a fusion protein of porcine complement C3d-P28 and ORF2 of porcine circovirus type 2 induces cross-protective immunity against PCV2b and PCV2d in pigs.
    Hou Z; Wang H; Feng Y; Li Q; Li J
    Virol J; 2019 May; 16(1):57. PubMed ID: 31046793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection.
    Opriessnig T; O'Neill K; Gerber PF; de Castro AM; Gimenéz-Lirola LG; Beach NM; Zhou L; Meng XJ; Wang C; Halbur PG
    Vaccine; 2013 Jan; 31(3):487-94. PubMed ID: 23174198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs.
    Fenaux M; Opriessnig T; Halbur PG; Elvinger F; Meng XJ
    J Virol; 2004 Jun; 78(12):6297-303. PubMed ID: 15163723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a porcine circovirus type 2a (PCV2a) vaccine efficacy against experimental PCV2a, PCV2b, and PCV2d challenge.
    Park KH; Oh T; Yang S; Cho H; Kang I; Chae C
    Vet Microbiol; 2019 Apr; 231():87-92. PubMed ID: 30955830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of experimental inactivated and live-attenuated chimeric porcine circovirus (PCV) 1-2b vaccines derived from PCV1 and PCV2b isolates originated in China.
    Li J; Yu T; Wang X; Zhou J; Gao R; Zhang F; Gao X; Gao S; Liu X
    Virol J; 2015 Jul; 12():113. PubMed ID: 26220290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capsid proteins from PCV2a genotype confer greater protection against a PCV2b strain than those from PCV2b genotype in pigs: evidence for PCV2b strains becoming more predominant than PCV2a strains from 2000 to 2010s.
    Huang L; Wang Y; Wei Y; Chen D; Liu D; Du W; Xia D; Wu H; Feng L; Liu C
    Appl Microbiol Biotechnol; 2016 Jul; 100(13):5933-43. PubMed ID: 27020283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell epitope content comparison (EpiCC) analysis demonstrates a bivalent PCV2 vaccine has greater T cell epitope overlap with field strains than monovalent PCV2 vaccines.
    Bandrick M; Gutiérrez AH; Desai P; Rincon G; Martin WD; Terry FE; De Groot AS; Foss DL
    Vet Immunol Immunopathol; 2020 May; 223():110034. PubMed ID: 32278900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A candidate inactivated chimeric vaccine PCV1-2 constructed based on PCV1 and PCV2 isolates originating in China and its evaluation in conventional pigs in regard to protective efficacy against PCV2 infection.
    Xujie L; Xiaobo W; Yi S; Jing F; Song G; Xiufan L
    Microbiol Immunol; 2011 Apr; 55(4):254-66. PubMed ID: 21244470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A commercial PCV2a-based vaccine is effective in protection from experimental challenge of PCV2 mutant with two amino acids elongation in capsid protein.
    Guo LJ; Fu YJ; Huang LP; Wang YP; Wei YW; Wu HL; Liu CM
    Vaccine; 2015 Jul; 33(31):3752-7. PubMed ID: 26051516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and phylogenetic analysis of the current porcine circovirus 2 genotypes after implementation of widespread vaccination programmes in the USA.
    Shen HG; Halbur PG; Opriessnig T
    J Gen Virol; 2012 Jun; 93(Pt 6):1345-1355. PubMed ID: 22398315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Porcine circovirus type 2a or 2b based experimental vaccines provide protection against PCV2d/porcine parvovirus 2 co-challenge.
    Opriessnig T; Karuppannan AK; Halbur PG; Calvert JG; Nitzel GP; Matzinger SR; Meng XJ
    Vaccine; 2020 Feb; 38(8):1975-1981. PubMed ID: 31974016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic diversity and different cross-neutralization capability of porcine circovirus type 2 isolates recently circulating in South Korea.
    Kang SJ; Kang H; You SH; Lee HJ; Lee N; Hyun BH; Cha SH
    BMC Vet Res; 2020 Sep; 16(1):334. PubMed ID: 32928247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of antigenic epitopes of porcine reproductive and respiratory syndrome virus (PRRSV) in a modified live-attenuated porcine circovirus type 2 (PCV2) vaccine virus (PCV1-2a) as a potential bivalent vaccine against both PCV2 and PRRSV.
    Piñeyro PE; Kenney SP; Giménez-Lirola LG; Heffron CL; Matzinger SR; Opriessnig T; Meng XJ
    Virus Res; 2015 Dec; 210():154-64. PubMed ID: 26239318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Porcine circovirus type 2b (PCV2b)-based experimental vaccine is effective in the PCV2b-Mycoplasma hyopneumoniae coinfection pig model.
    Opriessnig T; Castro AMMG; Karuppanan AK; Gauger PC; Halbur PG; Matzinger SR; Meng XJ
    Vaccine; 2019 Oct; 37(44):6688-6695. PubMed ID: 31537445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2.
    Opriessnig T; Gerber PF; Xiao CT; Halbur PG; Matzinger SR; Meng XJ
    Vaccine; 2014 Jul; 32(34):4342-8. PubMed ID: 24929119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A live-attenuated chimeric porcine circovirus type 2 (PCV2) vaccine is transmitted to contact pigs but is not upregulated by concurrent infection with porcine parvovirus (PPV) and porcine reproductive and respiratory syndrome virus (PRRSV) and is efficacious in a PCV2b-PRRSV-PPV challenge model.
    Opriessnig T; Shen HG; Pal N; Ramamoorthy S; Huang YW; Lager KM; Beach NM; Halbur PG; Meng XJ
    Clin Vaccine Immunol; 2011 Aug; 18(8):1261-8. PubMed ID: 21653745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An experimental live chimeric porcine circovirus 1-2a vaccine decreases porcine circovirus 2b viremia when administered intramuscularly or orally in a porcine circovirus 2b and porcine reproductive and respiratory syndrome virus dual-challenge model.
    Opriessnig T; Gomes-Neto JC; Hemann M; Shen HG; Beach NM; Huang Y; Halbur PG; Meng XJ
    Microbiol Immunol; 2011 Dec; 55(12):863-73. PubMed ID: 21951266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Porcine circovirus type 2 (PCV2) genotyping in Austrian pigs in the years 2002 to 2017.
    Weissenbacher-Lang C; Kristen T; Mendel V; Brunthaler R; Schwarz L; Weissenböck H
    BMC Vet Res; 2020 Jun; 16(1):198. PubMed ID: 32539835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.